Cytomegalovirus (CMV) infection in immunocompromised patients may result in severe morbidity and mortality. The standard of care for these patients is the use of CMV-seronegative blood components. Alternatively, filtered, leukocyte-reduced blood components have been used. However, neither approach completely prevented transfusion-associated CMV infection in the recipients. The Helinx ™ technology (Cerus Corp, Concord, CA) utilizing amotosalen hydrochloride (HCl) (S-59) and long-wavelength ultraviolet A (UVA) light, was developed to enhance the safety of platelet transfusion. The combination of 150 μmol/L of S-59 and a 3 J/cm 2 UVA treatment inactivated greater than 10 5.9 ± 0.3 plaque-forming units (pfus) per milliliter of CMV in full-sized therapeutic platelet concentrates. The efficacy margin of this treatment is greater than 100-fold. In an immunocompromised in vivo murine transfusion model, mice transfused with platelets contaminated with murine CMV (MCMV)-infected splenocytes became MCMV-positive, exhibited histologic evidence of CMV disease, and died. Mice transfused with Helinx-treated platelets contaminated with MCMV-infected splenocytes prior to treatment remained MCMV-negative with no histologic evidence of CMV disease and remained healthy. These results demonstrated that Helinx treatment of MCMV-contaminated platelet concentrates prevented MCMV infection by platelet transfusion in immunodeficient animals. In conclusion, Helinx technology offers a potential alternative to selection of CMV-seronegative units and to leukocyte-reduction filtration as a means to decrease the risk of transfusion-acquired CMV infection.
Seminars in Hematology – Elsevier
Published: Oct 1, 2001
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera